Physiological role for P2X1 receptors in renal microvascular autoregulatory behavior.
This study tests the hypothesis that P2X1 receptors mediate pressure-induced afferent arteriolar autoregulatory responses. Afferent arterioles from rats and P2X1 KO mice were examined using the juxtamedullary nephron technique. Arteriolar diameter was measured in response to step increases in renal perfusion pressure (RPP). Autoregulatory adjustments in diameter were measured before and during P2X receptor blockade with NF279 or A1 receptor blockade with 1,3-dipropyl-8-cyclopentylxanthine (DPCPX). Acute papillectomy or furosemide perfusion was performed to interrupt distal tubular fluid flow past the macula densa, thus minimizing tubuloglomerular feedback-dependent influences on afferent arteriolar function. Under control conditions, arteriolar diameter decreased by 17% and 29% at RPP of 130 and 160 mmHg, respectively. Blockade of P2X1 receptors with NF279 blocked pressure-mediated vasoconstriction, reflecting an attenuated autoregulatory response. The A1 receptor blocker DPCPX did not alter autoregulatory behavior or the response to ATP. Deletion of P2X1 receptors in KO mice significantly blunted autoregulatory responses induced by an increase in RPP, and this response was not further impaired by papillectomy or furosemide. WT control mice exhibited typical RPP-dependent vasoconstriction that was significantly attenuated by papillectomy. These data provide compelling new evidence indicating that tubuloglomerular feedback signals are coupled to autoregulatory preglomerular vasoconstriction through ATP-mediated activation of P2X1 receptors.
Inscho
Edward W
EW
Department of Physiology, Medical College of Georgia, 1120 15th Street, Augusta, Georgia 30912-3000, USA. einscho@mail.mcg.edu
Cook
Anthony K
AK
Imig
John D
JD
Vial
Catherine
C
Evans
Richard J
RJ
D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D004232:Diuretics / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005665:Furosemide / Q000494:pharmacology; D017353:Gene Deletion; D007668:Kidney / Q000098:blood supply*; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D008833:Microcirculation; D010477:Perfusion; D011312:Pressure; D051381:Rats; D017207:Rats, Sprague-Dawley; D018048:Receptors, Purinergic P2 / Q000502:physiology*; D058469:Receptors, Purinergic P2X; D012079:Renal Circulation; D013498:Suramin / Q000031:analogs & derivatives* / Q000494:pharmacology; D013997:Time Factors; D014970:Xanthines / Q000494:pharmacology
D004232:Diuretics; C114657:NF 279; D018048:Receptors, Purinergic P2; D058469:Receptors, Purinergic P2X; D014970:Xanthines; D013498:Suramin; D005665:Furosemide; D000255:Adenosine Triphosphate; C051360:1,3-dipropyl-8-cyclopentylxanthine